Vistagen Therapeutics Inc. ( (VTGN) ) has released its Q2 earnings. Here is a breakdown of the information Vistagen Therapeutics Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vistagen Therapeutics Inc., a late clinical-stage biopharmaceutical company, is pioneering the development of intranasal product candidates called pherines, aimed at treating conditions like social anxiety disorder without requiring absorption into the bloodstream.
Vistagen has reported its financial results for the second quarter of fiscal year 2026, highlighting the completion of the PALISADE-3 Phase 3 trial for fasedienol, a treatment for social anxiety disorder. The company anticipates releasing topline results by the end of the calendar year.
Key financial metrics include an increase in research and development expenses to $15.9 million, up from $10.2 million the previous year, driven by the ongoing PALISADE program. General and administrative expenses saw a slight rise to $4.4 million, while the net loss widened to $19.4 million from $13.0 million. Vistagen’s cash and marketable securities stood at $77.2 million as of September 30, 2025.
Strategically, Vistagen has strengthened its board with the appointment of Paul Edick, reflecting its commitment to advancing its clinical programs. The company remains focused on its PALISADE program, with the PALISADE-4 trial results expected in the first half of 2026.
Looking ahead, Vistagen’s management is optimistic about the potential of fasedienol to become the first FDA-approved acute treatment for social anxiety disorder, targeting a significant unmet need in the market.